AzTrials
AzTrials

Colorectal CancerPhase 3NCT00154752

Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer

A Phase 3 study testing CCRT, Pelvic lymphadenoectomy. in people with Colorectal Cancer, run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Based on the neurophysiology, it is well known that sympathetic nerves control the ejaculatory function and bladder neck closure. In contrast, the parasympathetic nerves control penile erection and bladder wall contraction. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Colorectal Cancer
What is being tested?
CCRT, Pelvic lymphadenoectomy.
Type of treatment
Surgery or procedure
How many people
200 participants
Where
1 siteTaiwan
Study dates
Jan 1999to Jun 2005
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Primary rectal adenocarcinoma below the peritoneal reflection 2. Tumor with suspected lateral nodes involvement and/or T4 lesion 3. ASA class Ⅰto Ⅲ patients 4. The life expectancy was greater than 12 weeks 5. Age of the patients between 18 and 75 years

Who cannot join

  • 1. Emergency operation 2. Primary tumors with distant metastasis or peritoneal carcinomatosis 3. Primary tumors located at other anatomical sites

Trial locations and contacts

1 site in 1 country.

Jin-Tung Liang, M.D., Ph.D. contact

886-2-23562068

jintung@ha.mc.ntu.edu.tw

Taiwan1 site, 1 recruiting
  • Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.

    Taipei, 100

    Jin-Tung Liang, M.D., Ph.D., 886-2-23562068, jintung@ha.mc.ntu.edu.tw

    Recruiting

Other trials in Taiwan

About this study

Official title: A Randomized Trial Comparing Concurrent Chemoradiation Versus Wide Pelvic Lymphadenectomy for Advanced Rectal Cancer

Based on the neurophysiology, it is well known that sympathetic nerves control the ejaculatory function and bladder neck closure. In contrast, the parasympathetic nerves control penile erection and bladder wall contraction. Because of the difference in cultural background of the patients and training background of the physicians between Western and Oriental Countries, the Western people did not believe in the efficacy of wide pelvic lymphadenectomy. In the Oriental countries, due to the shortage of standardized facilities, treatment protocol, and manpower, the concurrent preoperative chemoradiation therapy (CCRT) of American style is currently not widely accepted. Therefore, the advantage and disadvantage of these two treatment modalities for advanced rectal cancers need be further clarified. In this project, we plan to randomly assign the patients into two groups: (1) concurrent preoperative chemoradiation therapy (CCRT) + conventional surgery group; (2) wide pelvic lymphadenectomy group. Thereafter, we plan to evaluate: (1) the anorectal function by anorectal manometry and colonic transit time using radioopaque markers; (2) the micturition function using urodynamic study; (3) the penile erection by RigiScan; and (4) the ejaculatory function by clinical interview of the patients. Moreover, the various clinicopathologic factors, including the depth of tumor invasion and the status of lymph node invasion, were recorded in detail according to the guidelines recommended by the Japanese Society of Coloproctology. Furthermore, we will evaluate the oncological results for these patients.

Read the detailed description

This project is in continuation of our previous study (NTUH92-S044) and is focused on the comparison of the advantage and disadvantage of the following two treatment modalities: (1) preoperative neoadjuvant therapy (CCRT) followed by conventional surgery; (2) the Japanese-style of wide pelvic lymphadenectomy, for the treatment of potentially operable locally advanced rectal cancer. It is well-known that the keypoint for the surgical treatment of rectal cancer is to achieve a balance between 'radical resection of the tumor' and 'functional preservation for the pelvic organs'. Primary adenocarcinoma of the rectum is generally characterized by localized and comparatively slow-growing, as compared to the fast-growing tumors of other gastrointestinal malignancies. Thus, extended systemic pelvic lymphadenectomy has been considered the best choice for cure. However, there is major difference of concept between the Western and Oriental colorectal surgeons regarding the appropriate extent of lymphadenectomy for the treatment of rectal cancers lying below the peritoneal reflection. Theoretically, there are two major pathways for the lymphatic drainage of lower rectal cancers: one is upward to the root of inferior mesenteric artery (IMA); the other is along the middle hemorrhoidal artery to the obturator fossa. Because the American people tend to be very fatty and the pelvic lymphadenectomy is difficult to perform, most rectal cancer patients receive conventional limited resection combined with aggressive chemotherapy and pelvic irradiation. In contrast, because the Oriental people are thinner and pelvic lymphadenectomy is easier to perform, and most important of all, the Japanese surgeons were very meticulous in cancer surgery, the extended pelvic lymphadenectomy has become the routine procedure for the advanced lower rectal cancer in Japan. However, extended pelvic lymphadenectomy can inevitably cause the autonomic nerve damage, which thereafter result in the disturbance of micturition and sexual function. To overcome this genitourinary complication, the Japanese surgeon developed the autonomic nerve-sparing surgery. Generally speaking, pelvic autonomic nerves consist of sympathetic signals via the paired hypogastric nerves and paired sacral splanchnic nerves, and the parasympathetic signals via the pelvic splanchnic nerves. The sympathetic and parasympathetic fibers intermingled with each other to form the pelvic plexus, which is located at the lateral side of the lateral ligament. Pelvic plexus then send the composite autonomic signals to innervate distal rectum and genitourinary organs. Thus, the injury of autonomic nerve can reflect the functional disorder of the anorectum and genitourinary organs. Based on the neurophysiology, it is well known that sympathetic nerves control the ejaculatory function and bladder neck closure. In contrast, the parasympathetic nerves control penile erection and bladder wall contraction. Because of the difference in cultural background of the patients and training background of the physicians between Western and Oriental Countries, the Western people did not believe in the efficacy of wide pelvic lymphadenectomy. In the Oriental countries, due to the shortage of standardized facilities, treatment protocol, and manpower, the concurrent preoperative chemoradiation therapy (CCRT) of American style is currently not widely accepted. Therefore, the advantage and disadvantage of these two treatment modalities for advanced rectal cancers need be further clarified. In this project, we plan to randomly assign the patients into two groups: (1) concurrent preoperative chemoradiation therapy (CCRT) + conventional surgery group; (2) wide pelvic lymphadenectomy group. Thereafter, we plan to evaluate: (1) the anorectal function by anorectal manometry and colonic transit time using radioopaque markers; (2) the micturition function using urodynamic study ; (3) the penile erection by RigiScan; and (4) the ejaculatory function by clinical interview of the patients. Moreover, the various clinicopathologic factors, including the depth of tumor invasion and the status of lymph node invasion, were recorded in detail according to the guidelines recommended by the Japanese Society of Coloproctology. Furthermore, we will evaluate the oncological results for these patients. There are 2 characteristics for this project: (1) This is a randomized, prospective study which has not been conducted in the literature; (2) The functional evaluation is conducted in an objective way which is different from the reported series based only on the subjective patient interview.

During the conduction of our precious project (NTU 92-S044), we found that the response rate of locally advanced rectal cancer after CCRT is satisfactory. The response rate is even more increased after the addition of oxaliplatin to the traditional regimen of 5-Fu plus leucovorin. However, there was no significance patients between these 2 allocated groups of patients in terms of genitourinary dysfunction. These preliminary data need be further testified by accrual of more patients with longer time of follow-up. Therefore, it is mandatory for us to further perform this project. We believe that this study will provide a new balance point between the 'radical resection' and the 'functional preservation' for advanced rectal cancer patients.

Being tested
CCRT, Pelvic lymphadenoectomy.
Keywords
Rectal cancer, CCRT, Pelvic lymphadenoectomy.
Medical subject headings
Colorectal Neoplasms, Rectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CCRT, Pelvic lymphadenoectomy.Procedure or surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. oncologic results

Secondary outcomes (1)
  1. functional results

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2005 (estimated)
  2. Study startJan 1999
  3. Study completionJun 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00154752
Sponsor's protocol ID
9100013841
Status last verified
Jan 1999
First submitted
8 Sep 2005
Last updated
22 Nov 2005
Results posted
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing CCRT, Pelvic lymphadenoectomy. in people with Colorectal Cancer, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Nov 2005. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jin-Tung Liang, M.D., Ph.D. (886-2-23562068, jintung@ha.mc.ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

oncologic results. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2005.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in